זולג'נסמה
novartis israel ltd - onasemnogene abeparvovec - תרחיף - onasemnogene abeparvovec 2 x 10^13 vg / 1 ml - onasemnogene abeparvovec
ונופר
cts ltd - ferrous as iron iii hydroxide sucrose complex - תמיסה להזרקה - ferrous as iron iii hydroxide sucrose complex 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro-intestinal malobsorption which rules out oral therapy, patients on dialysis treated with erythropoietin.
ונופר
cts ltd - ferrous as iron iii hydroxide sucrose complex - תמיסה להזרקה - ferrous as iron iii hydroxide sucrose complex 100 mg / 5 ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro-intestinal malobsorption which rules out oral therapy, patients on dialysis treated with erythropoietin.
אמיודקור זריקות
sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.
רמיקד
j-c health care ltd - infliximab 100 mg/vial - powder for concentrate for infusion - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther
רמיקד
j-c health care ltd - infliximab - אבקה להכנת תרכיז לאינפוזיה - infliximab 100.0 mg/vial - infliximab - infliximab - - adult :crohn's disease: treatment of severe active crohn's disease in patients who have not responded despite of a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant. treatment of fistulising crohn's disease in patients who have not responded despite of a full and adequate course of therapy with conventional treatment. -paediatric crohn's disease: remicade is indicated for: treatment of severe active crohn's disease in paediatric patients aged 6 to 17 years who have not responded to conventional therapy including a corticosteroid an immunomodulator and primary nutrition therapy or who are intolerant to or have contraindications for such therapies. remicade has been studied only in combination with conventional immunosuppressive therapy -ankylosing spondylitis: remicade is indicated for: treatment of ankylosing spondylitis in patients who have severe axial symptoms elevated serological markers of inflammatory activity and who have responded inadequately to conventional ther
"orthadapt , biomatrix dermadapt "
"ס. י. ר. א. מ. בע""מ" - אחות - שתלים וחבישות המכילים חומר מן החי
gps iii platelet separation system
בפקס בע"מ - רופא - לניתוחי אורתופדיה
orthadapt , biomatrix dermadapt a
ס. י. ר. א. מ. בע"מ - אחות - שתלים וחבישות המכילים חומר מן החי
וילאט 1000
dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii